PathoCare Holdings, Inc. , based in Houston and the parent company of PathoCare, LLC, has accepted a third-party offer to buy shares from early investors.
Health Technology Insights: Human Longevity Pledges $1Million to Fight Ovarian Cancer
The value of the company is estimated at $500 million, as determined by Lehrer Financial. This deal, supported by the board of directors, helps early shareholders gain liquidity and plan for their estates while showing continued belief in the company’s diagnostic tools that use Raman spectroscopy and AI.
At the same time, PathoCare is starting a new private equity fundraising effort aiming to raise up to $25 million. This will help speed up the development and approval process for their main product, the PathoWand. This funding comes after a previous $150 million investment and restructuring led by Hamershlag Private Capital. Ownership is split 70% between Hamershlag Private Capital and the company’s founders.
Health Technology Insights: Wellsheet Launches Multidisciplinary AI Copilot To Reduce Charting Time By 50%
The new money will go towards engineering, testing, and getting the product to market. L. Mychal Jefferson, Chairman of PathoCare Holdings, said the tender offer shows confidence in the long-term potential of PathoCare’s diagnostic platform.
He added that the funds are not only rewarding early investors but also giving the company the resources to expand its innovative testing solutions. Lehrer Financial, known for its strict and thorough evaluation methods in healthcare and technology, looked at PathoCare’s patents, revenue predictions, and growth plans to arrive at the $500 million valuation. This move marks PathoCare’s shift from a research-focused company to a commercial-stage leader in diagnostic innovations.
Health Technology Insights: Nymbl Appoints Josh Davidson as Chief Technology Officer
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
